Prothya Biosolutions
Prothya Biosolutions B.V. is a European biopharmaceutical company that fractionates human blood plasma into therapeutic medicines for immunology and critical care, and offers CDMO manufacturing services to pharmaceutical partners. Acquired by Accord Plasma (Intas Pharmaceuticals) in October 2025, it operates from Belgium and the Netherlands.
- Company typePrivate
- Founded1957
- HeadquartersNeder-over-heembeek, Belgium
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prothya Biosolutions does
Prothya Biosolutions B.V. is a European plasma-derived biopharmaceutical company that fractionates human blood plasma into therapeutic medicines used in immunology and critical care, and offers contract development and manufacturing (CDMO) services to pharmaceutical partners. The company uses advanced protein isolation methods to convert plasma into medicines that treat immune deficiencies, hemophilia, and related conditions, distributing these branded products to healthcare providers and patients worldwide. Its two revenue streams are direct sales of plasma-derived medicinal products under its own brand, and B2B CDMO services that monetize its fractionation knowledge, validated manufacturing infrastructure, and process IP for external healthcare and pharmaceutical counterparties.
The company was formed in 2021 through the integration of Plasma Industries Belgium (PIBe), with roots in the Belgian Red Cross, and Sanquin Plasma Products (SPP), a former subsidiary of the Sanquin Blood Supply Foundation. Prothya draws on over 60 years of combined operational heritage in plasma collection and fractionation across its Belgian (Neder-over-heembeek) and Dutch operating sites, with a workforce of 1,001–5,000 employees. In January 2022 it consolidated European operations by acquiring Prothya Biosolutions Netherlands and Prothya Biosolutions Hungary Kft.
In October 2025, Accord Plasma B.V., a subsidiary of India's Intas Pharmaceuticals, completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries, integrating Prothya into a larger global plasma therapy network with stated objectives to expand patient access to plasma-derived medicines and increase manufacturing capacity. Under Intas/Accord ownership, Prothya's franchise combines legacy European operational depth with the parent's global commercialization footprint in plasma therapeutics.
Prothya Biosolutions firmographics
Firmographics- Name
- Prothya Biosolutions
- Legal name
- Prothya Biosolutions B.V.
- Website
- https://Prothya.com
- Company type
- Private
- Founded year
- 1957
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Prothya Biosolutions B.V. is a European biopharmaceutical company that fractionates human blood plasma into therapeutic medicines for immunology and critical care, and offers CDMO manufacturing services to pharmaceutical partners. Acquired by Accord Plasma (Intas Pharmaceuticals) in October 2025, it operates from Belgium and the Netherlands.
- Ownership category
- akta.pro rank
Prothya Biosolutions industry classification
Industry- Product category
- Plasma-derived Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)
- akta.pro secondary industries
- Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Prothya Biosolutions is headquartered
LocationHeadquarters
- HQ city
- Neder-over-heembeek
- HQ country
- Belgium
- HQ region
- Europe
Offices2 records
Markets served
Prothya Biosolutions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D
Revenue model
- Plasma-derived Medicinal Products: Prothya produces plasma-derived medicinal products under its own brand for use in immunology and critical care, generating revenue through product sales to healthcare providers and patients.
- CDMO Services: The company makes its knowledge and infrastructure available to various partners, providing contract development and manufacturing organization services to pharmaceutical and healthcare companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Prothya Biosolutions product offering
Product offeringCore offering
Prothya Biosolutions uses advanced methods to isolate proteins from human blood plasma and converts them into plasma-derived medicinal products for immunology and critical care applications, sold under its own brand. The company also offers Contract Development and Manufacturing Organization (CDMO) services, making its plasma processing knowledge and infrastructure available to pharmaceutical and healthcare partners worldwide.
Product overview
Prothya Biosolutions operates as a plasma-derived medicinal products company offering a portfolio centered on two main offerings: its own branded plasma-derived medicinal products for immunology and critical care applications, and Contract Development and Manufacturing Organization (CDMO) services that make its knowledge, infrastructure, and manufacturing capabilities available to pharmaceutical partners. The company uses advanced protein isolation methods to transform blood plasma into therapeutic medicines. Formed in 2021 through the integration of Plasma Industries Belgium (PIBe) and Sanquin Plasma Products (SPP), the company leverages over 60 years of combined experience in plasma collection and plasma-derived product manufacturing.
Differentiator
Problem solved
Functional benefit
Products and services
- Plasma-Derived Medicinal Products Prothya's branded plasma-derived medicinal products used in immunology and critical care, produced by isolating proteins from blood plasma through advanced fractionation methods. These therapies treat conditions such as immune deficiencies and hemophilia and are supplied to healthcare professionals and patients.
- CDMO Services Contract Development and Manufacturing Organization services where Prothya provides its plasma processing knowledge, infrastructure, and manufacturing capabilities to pharmaceutical and healthcare partners for plasma-derived product development and production.
Companies that use Prothya Biosolutions
Customer profileSegments3 records
Ideal customer profiles2 records
Prothya Biosolutions technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Prothya Biosolutions partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Prothya Biosolutions competitors and assessment
Company assessmentRegional players
- Sanquin Blood Supply Foundation: Sanquin is the former parent of SPP (now part of Prothya) and continues to operate the Dutch blood/plasma collection network that historically supplied Prothya's feed plasma, making it a closely adjacent rather than fully competing entity.
Broad incumbents
- Intas Pharmaceuticals: Intas is the parent of Accord Plasma (Prothya's new owner) and a broad Indian pharmaceutical conglomerate with generics, biosimilars, and plasma operations—related through ownership and corporate plasma strategy rather than direct product overlap.
Direct peers
- Biotest: Biotest develops and produces plasma proteins and biotherapeutic drugs with a focus on immunology, hematology, and intensive care, directly overlapping Prothya's portfolio and European-centric operations.
- Octapharma: Octapharma develops and manufactures plasma-derived proteins for immunology, hematology, and critical care from a European manufacturing base, competing head-to-head with Prothya in the same therapeutic areas.
- CSL Behring: CSL Behring is the global leader in plasma-derived therapeutics (immunoglobulins, albumin, clotting factors) and directly competes with Prothya across the same immunology and critical care product categories and fractionation technology base.
- Grifols: Grifols is one of the world's largest plasma fractionators, producing a near-identical portfolio of immunoglobulins, albumin, and clotting factors, and operates its own plasma collection network—directly comparable to Prothya's integrated model.
- Kedrion Biopharma: Kedrion is a European-headquartered plasma fractionator producing immunoglobulins, coagulation factors, and albumin with national blood-system partnerships—an almost exact analogue of Prothya's Belgian Red Cross and Sanquin roots.
- LFB Biomédicaments: LFB is a French state-linked plasma fractionator offering immunoglobulins, clotting factors, and albumin largely derived from volunteer donations through the French Blood Establishment—comparable to Prothya in both product mix and not-for-profit-rooted plasma sourcing.
- Takeda (Plasma-Derived Therapies): Takeda's Plasma-Derived Therapies business (inherited from Shire/Baxalta) is a direct competitor in immunoglobulin and albumin franchises, sharing Prothya's immunology and critical care focus and global CDMO-style scale-up capabilities.
Emerging players
- ADMA Biologics: ADMA Biologics is a smaller US-focused plasma-derived therapeutics company specializing in immune globulin products for immunodeficiency—partial overlap with Prothya's immunology franchise, but at a much smaller scale and narrow product mix.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Prothya Biosolutions social profiles
Digital presenceProthya Biosolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prothya Biosolutions leadership team
Management profileNumber of profiles
Profiles4 records
Prothya Biosolutions funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prothya Biosolutions M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prothya Biosolutions
What does Prothya Biosolutions do?
Prothya Biosolutions uses advanced methods to isolate proteins from human blood plasma and converts them into plasma-derived medicinal products for immunology and critical care applications, sold under its own brand. The company also offers Contract Development and Manufacturing Organization (CDMO) services, making its plasma processing knowledge and infrastructure available to pharmaceutical and healthcare partners worldwide.
Is Prothya Biosolutions a public or private company?
Prothya Biosolutions is a private company. It is classified as corporate owned and is currently operating.
When was Prothya Biosolutions founded?
Prothya Biosolutions was founded in 1957. It employs 1,001 to 5,000 people.
Where is Prothya Biosolutions based?
Prothya Biosolutions is headquartered in Neder-over-heembeek, Belgium, in the Europe region.
How does Prothya Biosolutions make money?
Two revenue lines are on record. Plasma-derived Medicinal Products are the primary driver. The others are CDMO Services.
Who are Prothya Biosolutions's main competitors?
Sanquin Blood Supply Foundation is listed as a regional player. Intas Pharmaceuticals is listed as a broad incumbent. Direct peers are Biotest, Octapharma, CSL Behring, Grifols, Kedrion Biopharma, LFB Biomédicaments and Takeda (Plasma-Derived Therapies). ADMA Biologics is listed as an emerging player.
Does Prothya Biosolutions have an API?
No public API is recorded for Prothya Biosolutions.
What industry is Prothya Biosolutions in?
Prothya Biosolutions's product category is Plasma-derived Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors), with a secondary code of HLAIAHAI, Plasma Fractionation & Purification Manufacturing. Its NAICS code is 325414 and its SIC code is 2836.